{"schema_version":"1","generated_at":"2026-11-08T11:34:30.203Z","data_as_of":null,"url":"https://www.findmykol.com/kol/carla-falkson","json_url":"https://www.findmykol.com/kol/carla-falkson/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"carla-falkson","name":"Carla Falkson","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"institution":"University of Rochester Medicine","institution_url":"https://www.findmykol.com/institution/university-of-rochester-medicine","city":"Rochester","state":"NY","region":{"label":"Northeast","url":"https://www.findmykol.com/region/northeast"}},"identifiers":{"npi":"1538103122","orcid":"0000-0003-2370-6818","openalex":"A5085329460"},"summary":"Carla Falkson is an Oncology physician affiliated with University of Rochester Medicine. OpenAlex indexes 157 publications with 5,165 citations (h-index 34); ClinicalTrials.gov lists 2 registered studies matched to this name.","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":157,"cited_by_count":5165,"h_index":34,"latest_activity_year":2025,"source":"works"},"trials":{"count":2,"shown":2,"withheld":0,"matched_by":"investigator name, confirmed against institution and geography","rows":[{"nct":"NCT00240071","title":"Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.","phase":"PHASE2","status":"COMPLETED","role":"Overall official","sponsor":"University of Alabama at Birmingham","source_url":"https://clinicaltrials.gov/study/NCT00240071","trial_url":"https://www.findmykol.com/trial/NCT00240071"},{"nct":"NCT00127205","title":"S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.","phase":"PHASE3","status":"COMPLETED","role":"Overall official","sponsor":"SWOG Cancer Research Network","source_url":"https://clinicaltrials.gov/study/NCT00127205","trial_url":"https://www.findmykol.com/trial/NCT00127205"}],"source":"trials"},"payments":{"company_count":4,"program_years":{"first":2021,"last":null},"rows_total":16,"shown":3,"withheld":13,"rows":[{"payer":"Daiichi Sankyo Inc.","program_year":2025,"amount_usd":280.36,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1538103122"},{"payer":"Gilead Sciences, Inc.","program_year":2025,"amount_usd":189.85,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1538103122"},{"payer":"Merck Sharp & Dohme LLC","program_year":2025,"amount_usd":105.6,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1538103122"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1538103122","source":"payments"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial","year":2024,"journal":"Nature Medicine","source_url":"https://doi.org/10.1038/s41591-024-03267-1","status":"verified"},{"title":"Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer","year":2024,"journal":"Cancers","source_url":"https://doi.org/10.3390/cancers16030619","status":"verified"},{"title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030","year":2023,"journal":"Annals of Oncology","source_url":"https://doi.org/10.1016/j.annonc.2023.08.004","status":"verified"},{"title":"Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL","year":2023,"journal":"Cancer Research","source_url":"https://doi.org/10.1158/1538-7445.sabcs22-gs5-03","status":"verified"},{"title":"BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer","year":2021,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.21.01657","status":"verified"}],"source":"works"},"contact":{"address_1":"125 RED CREEK DR","city":"Rochester","state":"NY","zip":"146234272","phone":"585-486-0600","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1538103122","source":"identity"},"similar":[{"name":"Lisa Beck","slug":"lisa-beck","institution":"University of Rochester Medicine","specialty":"Dermatology","url":"https://www.findmykol.com/kol/lisa-beck","json_url":"https://www.findmykol.com/kol/lisa-beck/profile.json"},{"name":"Benzi Kluger","slug":"benzi-kluger","institution":"University of Rochester Medicine","specialty":"Neurology","url":"https://www.findmykol.com/kol/benzi-kluger","json_url":"https://www.findmykol.com/kol/benzi-kluger/profile.json"},{"name":"Darren Tabechian","slug":"darren-tabechian","institution":"University of Rochester Medicine","specialty":"Rheumatology","url":"https://www.findmykol.com/kol/darren-tabechian","json_url":"https://www.findmykol.com/kol/darren-tabechian/profile.json"},{"name":"Ayesa Mian","slug":"ayesa-mian","institution":"University of Rochester Medicine","specialty":"Pediatric Nephrology","url":"https://www.findmykol.com/kol/ayesa-mian","json_url":"https://www.findmykol.com/kol/ayesa-mian/profile.json"},{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":13,"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2023-06-30","provider_certified":"2019-12-12","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"trials":{"name":"ClinicalTrials.gov","url":"https://clinicaltrials.gov","provides":"Investigator roles on registered clinical studies"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"}},"methodology_url":"https://www.findmykol.com/about#methodology"}